Cellectar Biosciences, Inc.

Creating the Next Generation of Targeted Cancer Therapies

We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid drug conjugates™ (PDCs™) delivery platform to develop PDCs that specifically target cancer cells to deliver improved efficacy and better safety as a result of fewer off-target effects. The PDC™ platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments and we plan to develop PDCs independently and through research and development collaborations.

About Cellectar

A Multi-Asset Product Portfolio of Chemotherapeutics

We employ a drug discovery and development approach that allows us to efficiently design, research and advance drug candidates. In two years, we have successfully advanced our lead PDC, CLR 131 into multiple Phase 2 clinical trials. Additionally, we have initiated three collaborations and two proprietary programs that are rapidly progressing toward clinical trials.

Explore Our Pipeline

Advancing Innovation in Targeted Therapies

With the challenges that have faced other targeted therapeutic approaches, we have focused on developing the next generation of targeted therapies leveraging our PLE platform technology. We combine knowledge of targeting specificity, uptake and intracellular trafficking, and novel linker chemistry and release mechanisms to allow both a greater diversity in warhead delivery and potentially greater efficacy.

View Our Technology

Press Releases

Apr 17, 2018

Cellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating Efficacy of Fractionated Injections of CLR 131 in Multiple Myeloma

Apr 16, 2018

Cellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating the Ability of its PDCs to Selectively Target a Broad Range of Tumor Cells

Apr 16, 2018

Preclinical Data Highlighting Uptake and Enhanced Anti-Tumor Effects of Cellectar’s CLR 131 in Head and Neck Cancer Presented at AACR Annual Meeting

View all news

Stock Information

View Investor Relations View Investor Presentation

IR Contact Information

Investor Relations

LHA Investor Relations
Miriam Weber Miller
T: 212-838-3777
MMiller@lhai.com

Social Media

Market Data copyright © 2018 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.